Matinas BioPharma Holdings (MTNB) Other Working Capital Changes (2013 - 2026)
Matinas BioPharma Holdings (MTNB) reported Other Working Capital Changes of $8302.0 for Q1 2026, down 95.86% year-over-year from $200766.0 in Q1 2025, and up 101.72% quarter-over-quarter from -$484000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Other Working Capital Changes (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 14 years of Other Working Capital Changes data on file, last reported at $8302.0 in Q1 2026.
- Other Working Capital Changes for Q1 2026 came in at $8302.0, down 95.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $8302.0 (down 95.86% YoY), and the FY2025 annual result was $343536.0, up 489.57% from the prior year.
- Other Working Capital Changes improved to $8302.0 in Q1 2026 per MTNB's latest filing, from -$484000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $1.5 million in Q4 2022 and troughed at -$2.4 million in Q1 2023.
- A 5-year average of $227490.6 and a median of $336458.0 in 2025 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes tumbled 761.2% in 2023, then soared 1634.29% in 2024.
- A 5-year view of Other Working Capital Changes shows it stood at $1.5 million in 2022, then plunged by 109.93% to -$151000.0 in 2023, then gained by 29.8% to -$106000.0 in 2024, then sank by 356.6% to -$484000.0 in 2025, then soared by 101.72% to $8302.0 in 2026.
- Business Quant data shows MTNB's Other Working Capital Changes at $8302.0 in Q1 2026, -$484000.0 in Q4 2025, and $343536.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,302.00 |
| Mar 31, 2026 | 8,302.00 |
| Dec 31, 2025 | -484,000.00 |
| Dec 31, 2025 | -484,000.00 |
| Sep 30, 2025 | 343,536.00 |
| Sep 30, 2025 | 343,536.00 |
| Jun 30, 2025 | 336,458.00 |
| Jun 30, 2025 | 336,458.00 |
| Mar 31, 2025 | 200,766.00 |
| Mar 31, 2025 | 200,766.00 |
| Dec 31, 2024 | -106,000.00 |
| Dec 31, 2024 | -106,000.00 |
| Sep 30, 2024 | 43,531.00 |
| Sep 30, 2024 | 43,531.00 |
| Jun 30, 2024 | 676,374.00 |
| Jun 30, 2024 | 676,374.00 |
| Mar 31, 2024 | 676,374.00 |
| Mar 31, 2024 | 676,374.00 |
| Dec 31, 2023 | -151,000.00 |
| Dec 31, 2023 | -151,000.00 |